Drug Res (Stuttg) 2013; 63(11): 602
DOI: 10.1055/s-0033-1357211
© Georg Thieme Verlag KG Stuttgart · New York
Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen
B. Bittner
1
F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
2
F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland
,
W. F. Richter
3
F. Hoffmann-La Roche Ltd., Nonclinical Safety, Basel, Switzerland
,
F. Hourcade-Potelleret
4
F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland
,
C. McIntyre
1
F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
,
F. Herting
5
Roche Diagnostics GmbH, Penzberg, Germany
,
M. L. Zepeda
6
Halozyme Therapeutics Inc., San Diego, CA, USA
,
J. Schmidt
2
F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland
› Author Affiliations
